Predictive oncology adjourns special meeting of stockholders

Minneapolis, april 17, 2023 (globe newswire) -- predictive oncology (nasdaq: poai), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, clinical laboratory improvement amendments (clia) laboratory and good manufacturing practices (gmp) facility, to accelerate oncology drug discovery and enable drug development, announced today that the company's special meeting of stockholders was convened at 3:00 p.m. central time on april 17, 2023 and adjourned without any business being conducted, due to lack of the required quorum. due to the lack of quorum, the special meeting was adjourned to allow additional time for the company's stockholders to vote on the proposal to approve an amendment to the company's certificate of incorporation to effect a reverse stock split of the outstanding shares of its common stock at a ratio of not less than one-for-two (1:2) and not more than one-for-twenty-five (1:25), with the exact ratio to be set at a whole number within this range as determined by our board of directors. at the special meeting, the stockholders are also being asked to approve a proposal to adjourn the special meeting, if necessary, to solicit additional proxies for approval of the reverse split proposal, in the event that there are not sufficient votes at the time of the special meeting to approve such proposal.
POAI Ratings Summary
POAI Quant Ranking